161 related articles for article (PubMed ID: 37821202)
1. Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Kessel C
Rheum Dis Clin North Am; 2023 Nov; 49(4):895-911. PubMed ID: 37821202
[TBL] [Abstract][Full Text] [Related]
2. Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease.
Brown RA; Henderlight M; Do T; Yasin S; Grom AA; DeLay M; Thornton S; Schulert GS
Front Immunol; 2018; 9():2995. PubMed ID: 30619348
[No Abstract] [Full Text] [Related]
3. Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.
Vandenhaute J; Wouters CH; Matthys P
Front Immunol; 2019; 10():3089. PubMed ID: 32010140
[TBL] [Abstract][Full Text] [Related]
4. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.
Ambler WG; Nanda K; Onel KB; Shenoi S
Ann Med; 2022 Dec; 54(1):1839-1850. PubMed ID: 35786149
[TBL] [Abstract][Full Text] [Related]
5. Treatment of systemic juvenile idiopathic arthritis.
Hinze CH; Foell D; Kessel C
Nat Rev Rheumatol; 2023 Dec; 19(12):778-789. PubMed ID: 37923864
[TBL] [Abstract][Full Text] [Related]
6. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
7. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
8. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
9. Proceedings from the 2
Canna SW; Schulert GS; de Jesus A; Pickering A; Brunner H; Gadina M; Levine S; Goldbach-Mansky R; Boutelle J; Sinha R; DeBenedetti F; Grom A;
Pediatr Rheumatol Online J; 2020 Jul; 18(Suppl 1):53. PubMed ID: 32664935
[TBL] [Abstract][Full Text] [Related]
10. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies.
Pardeo M; Bracaglia C; De Benedetti F
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):505-516. PubMed ID: 29773270
[TBL] [Abstract][Full Text] [Related]
11. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
Schulert GS; Pickering AV; Do T; Dhakal S; Fall N; Schnell D; Medvedovic M; Salomonis N; Thornton S; Grom AA
Ann Rheum Dis; 2021 May; 80(5):617-625. PubMed ID: 33277241
[TBL] [Abstract][Full Text] [Related]
12. Systemic JIA: new developments in the understanding of the pathophysiology and therapy.
Vastert SJ; Kuis W; Grom AA
Best Pract Res Clin Rheumatol; 2009 Oct; 23(5):655-64. PubMed ID: 19853830
[TBL] [Abstract][Full Text] [Related]
13. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era.
Ailioaie LM; Ailioaie C; Litscher G
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361547
[TBL] [Abstract][Full Text] [Related]
15. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Yasin S; Fall N; Brown RA; Henderlight M; Canna SW; Girard-Guyonvarc'h C; Gabay C; Grom AA; Schulert GS
Rheumatology (Oxford); 2020 Feb; 59(2):361-366. PubMed ID: 31326996
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.
Erkens R; Esteban Y; Towe C; Schulert G; Vastert S
Rheum Dis Clin North Am; 2021 Nov; 47(4):585-606. PubMed ID: 34635293
[TBL] [Abstract][Full Text] [Related]
17. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
[No Abstract] [Full Text] [Related]
18. Systemic Juvenile Idiopathic Arthritis.
Lee JJY; Schneider R
Pediatr Clin North Am; 2018 Aug; 65(4):691-709. PubMed ID: 30031494
[TBL] [Abstract][Full Text] [Related]
19. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Inoue N; Schulert GS
Arthritis Res Ther; 2023 Mar; 25(1):48. PubMed ID: 36964620
[TBL] [Abstract][Full Text] [Related]
20. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
